Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 4, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 4, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development
Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles
(heparin sodium + lidocaine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAY-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women’s Health Conference
Sep 12, 2018: U.S. Department of Defense awards $3.3 million grant to Alivio Therapeutics
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
Jun 30, 2011: Urigen Provides Development Update For URG101
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
Apr 23, 2010: Urigen Files Request For FDA Meeting
Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
Apr 25, 2008: Urigen Announces US Patent Office Notice Of Allowance Of Claims For URG101
Apr 07, 2008: Urigen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Analysis Results
Dec 05, 2007: Urigen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development
Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles
(heparin sodium + lidocaine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAY-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women’s Health Conference
Sep 12, 2018: U.S. Department of Defense awards $3.3 million grant to Alivio Therapeutics
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
Jun 30, 2011: Urigen Provides Development Update For URG101
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
Apr 23, 2010: Urigen Files Request For FDA Meeting
Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
Apr 25, 2008: Urigen Announces US Patent Office Notice Of Allowance Of Claims For URG101
Apr 07, 2008: Urigen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Analysis Results
Dec 05, 2007: Urigen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Alivio Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by GlycoMira Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Grunenthal GmbH, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Harrow Health Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Mirae Cell Bio Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products, H2 2019
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Alivio Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by GlycoMira Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Grunenthal GmbH, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Harrow Health Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Mirae Cell Bio Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
